{"id":11317,"date":"2022-07-01T20:32:33","date_gmt":"2022-07-02T00:32:33","guid":{"rendered":"https:\/\/www.cancerresearch.org\/event\/immunotherapy-for-brain-cancer\/"},"modified":"2022-07-14T15:57:59","modified_gmt":"2022-07-14T19:57:59","slug":"immunotherapy-for-brain-cancer","status":"publish","type":"cri_events","link":"https:\/\/www.cancerresearch.org\/es\/events\/immunotherapy-for-brain-cancer","title":{"rendered":"Immunotherapy for Brain Cancer"},"content":{"rendered":"<p style=\"text-align:center\"><iframe loading=\"lazy\" allowfullscreen=\"\" frameborder=\"0\" height=\"360\" src=\"https:\/\/www.youtube.com\/embed\/2QanZ5CrjsM\" width=\"640\"><\/iframe><\/p>\n<p>On April 24, 2014, David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, discussed current immunotherapy treatment options for patients with brain cancer, and how close we are to making these treatments available to more patients.<\/p>\n<p>Dr. Reardon previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for eleven years. He completed his residency at John Hopkins Hospital in Maryland, and was awarded a fellowship at the University of Michigan. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors. His work includes using innovative clinical therapeutic agents to improve cure rates in patients with brain and spinal tumors, with particular focus on immunotherapeutics as well as molecular-targeting agents. In 2013, he was elected as the tenth president of the Society for Neuro-Oncology.<\/p>\n<p>This webinar is part of the Cancer Research Institute&#39;s webinar series, &quot;Cancer Immunotherapy and You,&quot; which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&amp;A. For more information on this webinar, or to register for upcoming webinars, please visit <a href=\"https:\/\/www.cancerresearch.org\/webinars\" target=\"_blank\" rel=\"noopener\">www.cancerresearch.org\/webinars<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. David A. Reardon of&nbsp;Dana-Farber Cancer Institute&nbsp;discusses current immunotherapy treatment options for patients with brain cancer, and how close we are to making these treatments available to more patients.<\/p>\n","protected":false},"featured_media":3253,"template":"","events_categories":[198],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-11317","cri_events","type-cri_events","status-publish","has-post-thumbnail","hentry","events_categories-webinars"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunotherapy for Brain Cancer<\/title>\n<meta name=\"description\" content=\"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunotherapy for Brain Cancer\" \/>\n<meta property=\"og:description\" content=\"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-14T19:57:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/444d6a75-f5bf-452e-a119-e9dd8269ec02.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Immunotherapy for Brain Cancer\" \/>\n<meta name=\"twitter:description\" content=\"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/444d6a75-f5bf-452e-a119-e9dd8269ec02.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer\",\"url\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer\",\"name\":\"Immunotherapy for Brain Cancer\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg\",\"datePublished\":\"2022-07-02T00:32:33+00:00\",\"dateModified\":\"2022-07-14T19:57:59+00:00\",\"description\":\"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg\",\"width\":320,\"height\":208},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Event\",\"item\":\"https:\/\/www.cancerresearch.org\/events\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Immunotherapy for Brain Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunotherapy for Brain Cancer","description":"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer","og_locale":"es_ES","og_type":"article","og_title":"Immunotherapy for Brain Cancer","og_description":"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.","og_url":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer","og_site_name":"Cancer Research Institute","article_modified_time":"2022-07-14T19:57:59+00:00","og_image":[{"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/444d6a75-f5bf-452e-a119-e9dd8269ec02.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"Immunotherapy for Brain Cancer","twitter_description":"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.","twitter_image":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/444d6a75-f5bf-452e-a119-e9dd8269ec02.jpg","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer","url":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer","name":"Immunotherapy for Brain Cancer","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg","datePublished":"2022-07-02T00:32:33+00:00","dateModified":"2022-07-14T19:57:59+00:00","description":"Dr. David A. Reardon of\u00a0Dana-Farber Cancer Institute\u00a0discusses current immunotherapy treatment options for patients with brain cancer.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/836dff6a-9a2c-4bef-bcda-5dc4cf57304f.jpg","width":320,"height":208},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/events\/immunotherapy-for-brain-cancer#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Event","item":"https:\/\/www.cancerresearch.org\/events"},{"@type":"ListItem","position":3,"name":"Immunotherapy for Brain Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events\/11317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_events"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_events"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/3253"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=11317"}],"wp:term":[{"taxonomy":"events_categories","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/events_categories?post=11317"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=11317"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=11317"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=11317"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=11317"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=11317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}